130 related articles for article (PubMed ID: 17370647)
1. [Molecular imaging in the drug development of psychotropics using positron emission tomography].
Takano H; Takahashi H; Ito H; Suhara T
Brain Nerve; 2007 Mar; 59(3):215-20. PubMed ID: 17370647
[TBL] [Abstract][Full Text] [Related]
2. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development.
Talbot PS; Laruelle M
Eur Neuropsychopharmacol; 2002 Dec; 12(6):503-11. PubMed ID: 12468013
[TBL] [Abstract][Full Text] [Related]
3. No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study.
Ito H; Arakawa R; Takahashi H; Takano H; Okumura M; Otsuka T; Ikoma Y; Shidahara M; Suhara T
Int J Neuropsychopharmacol; 2009 Jun; 12(5):667-75. PubMed ID: 18937879
[TBL] [Abstract][Full Text] [Related]
4. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
[TBL] [Abstract][Full Text] [Related]
5. [Imaging blood-brain barrier function by using positron emission tomography to evaluate drug penetration into the brain].
Takano H; Suhara T
Brain Nerve; 2013 Feb; 65(2):137-43. PubMed ID: 23399671
[TBL] [Abstract][Full Text] [Related]
6. [Significance of imaging biomarkers in exploratory clinical trials].
Takano H; Suhara T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):55-9. PubMed ID: 19562942
[TBL] [Abstract][Full Text] [Related]
7. The antipsychotic sultopride is overdosed--a PET study of drug-induced receptor occupancy in comparison with sulpiride.
Takano A; Suhara T; Yasuno F; Suzuki K; Takahashi H; Morimoto T; Lee YJ; Kusuhara H; Sugiyama Y; Okubo Y
Int J Neuropsychopharmacol; 2006 Oct; 9(5):539-45. PubMed ID: 16288681
[TBL] [Abstract][Full Text] [Related]
8. [In vivo evaluation of expressed protein function by PET].
Matsumoto R; Suhara T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):137-41. PubMed ID: 16045196
[TBL] [Abstract][Full Text] [Related]
9. PET technology for drug development in psychiatry.
Arakawa R; Takano A; Halldin C
Neuropsychopharmacol Rep; 2020 Jun; 40(2):114-121. PubMed ID: 32463584
[TBL] [Abstract][Full Text] [Related]
10. Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters.
Yahata M; Chiba K; Watanabe T; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2345-2356. PubMed ID: 28501470
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic plasma concentrations of antidepressants and antipsychotics: lessons from PET imaging.
Gründer G; Hiemke C; Paulzen M; Veselinovic T; Vernaleken I
Pharmacopsychiatry; 2011 Sep; 44(6):236-48. PubMed ID: 21959785
[TBL] [Abstract][Full Text] [Related]
12. Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2.
Moriguchi S; Takano H; Kimura Y; Nagashima T; Takahata K; Kubota M; Kitamura S; Ishii T; Ichise M; Zhang MR; Shimada H; Mimura M; Meyer JH; Higuchi M; Suhara T
Int J Neuropsychopharmacol; 2017 Dec; 20(12):957-962. PubMed ID: 29016875
[TBL] [Abstract][Full Text] [Related]
13. [Molecular imaging for pharmacodynamics of psychotropic drugs].
Suhara T
Seishin Shinkeigaku Zasshi; 2007; 109(9):869-75. PubMed ID: 18213899
[No Abstract] [Full Text] [Related]
14. Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter.
Saijo T; Maeda J; Okauchi T; Maeda J; Morio Y; Kuwahara Y; Suzuki M; Goto N; Suzuki K; Higuchi M; Suhara T
Int J Neuropsychopharmacol; 2009 Sep; 12(8):1021-32. PubMed ID: 19236731
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of PET in clinical trials of psychotropic drugs].
Suhara T; Morimoto T
Seishin Shinkeigaku Zasshi; 2005; 107(7):704-11. PubMed ID: 16250122
[No Abstract] [Full Text] [Related]
17. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).
Nogami T; Takano H; Arakawa R; Ichimiya T; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Takahata K; Suzuki M; Nagashima T; Mori T; Shimada H; Fukuda H; Sekine M; Tateno A; Takahashi H; Ito H; Okubo Y; Suhara T
Int J Neuropsychopharmacol; 2013 Jun; 16(5):937-43. PubMed ID: 23067569
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein.
de Vries EF; Kortekaas R; van Waarde A; Dijkstra D; Elsinga PH; Vaalburg W
J Nucl Med; 2005 Aug; 46(8):1384-92. PubMed ID: 16085598
[TBL] [Abstract][Full Text] [Related]
19. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
